BMS India Introduces RELOPDUO™ for Metastatic Melanoma

Mumbai, India, 27 July 2026 – Bristol Myers Squibb (BMS) announced the launch of RELOPDUO™ [fixed-dose combination (FDC) of nivolumab and relatl imab] in India following an approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services (DGHS), authorising its sale and distribution. With this milestone,...